# Pulmonary Function Testing - Spirometry and Lung Volumes

## Introduction and Indications

### Clinical Context

Pulmonary function tests remain the cornerstone of objective respiratory assessment, providing quantitative measures of lung mechanics that are indispensable for diagnosis, monitoring, and prognostication across the full spectrum of respiratory disease. However, no PFT result should be interpreted in isolation; the clinician must integrate spirometric data with the patient's clinical history, physical examination findings, and imaging to arrive at a meaningful clinical conclusion. The ATS/ERS 2022 updated standards for spirometry standardization represent the most current technical guidelines governing test performance, acceptability criteria, and quality assurance. Of equal importance is the selection of appropriate reference equations. The Global Lung Initiative (GLI) 2012 reference equations are now preferred over the older NHANES III reference values, as they were derived from a large, multi-ethnic, international dataset and employ sophisticated statistical modeling to generate age-, height-, and sex-specific predicted values with reliable lower limits of normal. A significant and ongoing debate surrounds the use of race-neutral reference equations, as advocated in the ATS 2023 statement (GLI Global 2022 equations), which aim to eliminate the practice of adjusting predicted values based on race or ethnicity. The clinical implications of this transition remain an active area of investigation.

### Indications for Spirometry

Spirometry is indicated for the diagnosis and longitudinal monitoring of both obstructive and restrictive lung diseases, including asthma, COPD, and interstitial lung disease. It plays a critical role in preoperative risk assessment, particularly before lung resection surgery, where predicted postoperative FEV1 and DLCO inform surgical candidacy. Spirometry is essential in the evaluation of disability and impairment for occupational and medicolegal purposes, providing objective evidence of functional limitation. It is also used to monitor drug toxicity in patients receiving medications known to cause pulmonary injury, such as amiodarone, bleomycin, and nitrofurantoin, where serial testing can detect early decline before symptoms manifest. Finally, spirometry serves as a surveillance tool in occupational settings, screening workers exposed to agents such as asbestos, silica, and coal dust for early evidence of respiratory impairment.

## Spirometry: Technical Standards and Interpretation

### Acceptability and Repeatability Criteria (ATS/ERS 2019/2022)

The reliability of spirometric data depends upon rigorous adherence to standardized acceptability and repeatability criteria. A minimum of three acceptable maneuvers must be obtained, with a maximum of eight attempts recommended before concluding the session. Each maneuver must demonstrate a rapid and maximal effort at onset, as quantified by the back-extrapolated volume, which should be less than 5% of the FVC or 100 mL, whichever is greater. The end-of-test criterion requires either a plateau in the volume-time curve (defined as no change greater than 25 mL for at least 1 second) or an expiratory time of at least 15 seconds. Repeatability is assessed by comparing the two largest FVC values, which must fall within 150 mL of each other, and the two largest FEV1 values, which must also fall within 150 mL. In patients with an FVC less than 1.0 L, the repeatability criterion is tightened to 100 mL, reflecting the proportionally greater impact of small measurement variability in this population.

### Key Spirometric Parameters

The forced expiratory volume in one second (FEV1) represents the volume of air expelled during the first second of a forced expiratory maneuver. This parameter is effort-dependent during its early phase and serves as a cornerstone for grading the severity of airflow obstruction. The forced vital capacity (FVC) measures the total volume of air exhaled during the entire forced maneuver from full inspiration to maximal expiration. The FEV1/FVC ratio is the primary determinant of obstruction, and it is critical to interpret this value as an absolute ratio rather than as a percent of predicted, since using percent predicted introduces age-related bias. The forced expiratory flow between 25% and 75% of FVC (FEF25-75) reflects mid-expiratory flow rates and has been proposed as an early marker of small airway disease. However, its clinical utility is severely limited by high intra- and inter-individual variability, and it should not be used as a standalone diagnostic parameter. Peak expiratory flow (PEF) is highly effort-dependent and finds its greatest utility in the serial monitoring of asthma control and in the assessment of potential malingering during disability evaluations.

### Defining Obstruction

| Severity Grade (ATS/ERS) | FEV1 % Predicted | Clinical Significance |
|--------------------------|------------------|----------------------|
| Normal | >= 80% | No significant obstruction |
| Mild | >= 70% | Often asymptomatic at rest |
| Moderate | 60–69% | Exertional dyspnea common |
| Moderately Severe | 50–59% | Activity limitation |
| Severe | 35–49% | Significant functional impairment |
| Very Severe | < 35% | Dyspnea at rest; consider transplant referral |

Airflow obstruction is defined by an FEV1/FVC ratio that falls below the lower limit of normal (LLN) as determined by the GLI reference equations. The alternative approach, widely promoted by the GOLD initiative for COPD, uses a fixed ratio cutoff of less than 0.70. While the fixed ratio is simpler to apply, it carries the significant limitation of overdiagnosing obstruction in elderly individuals, in whom the physiologic decline in FEV1/FVC with age may push the ratio below 0.70 in the absence of disease, and underdiagnosing obstruction in young adults, whose normal ratio is substantially higher. Once obstruction is established, severity is graded by the FEV1 percent predicted according to the ATS/ERS classification: mild (FEV1 at or above 70% predicted), moderate (60-69%), moderately severe (50-59%), severe (35-49%), and very severe (below 35%).

### Bronchodilator Responsiveness

Bronchodilator responsiveness testing is performed by administering 400 mcg of salbutamol via a metered-dose inhaler with spacer and repeating spirometry after a 15- to 20-minute interval. A positive response has traditionally been defined as an increase in FEV1 and/or FVC of at least 200 mL and at least 12% from the baseline value. The ATS/ERS 2022 guidelines have suggested that an absolute change of at least 10% of the predicted value may serve as a more robust criterion, as it is less influenced by baseline lung function. It is important to recognize that a negative bronchodilator response does not exclude the diagnosis of asthma, since bronchodilator responsiveness can vary over time and may be absent during periods of well-controlled disease.

<image>A detailed medical diagram showing the flow-volume loop with labeled axes (flow in L/s on Y-axis, volume in liters on X-axis). Display a normal loop in blue, an obstructive pattern in red (showing scooped expiratory limb with reduced peak flow), and a restrictive pattern in green (showing a tall narrow loop with reduced volume but preserved shape). Label key points including peak expiratory flow, FEF25, FEF50, FEF75, and the inspiratory limb. Include small inset volume-time curves for each pattern.</image>

## Lung Volumes

### Methods of Measurement

The accurate determination of lung volumes requires techniques capable of measuring the residual volume, which cannot be assessed by spirometry alone. Body plethysmography is considered the gold standard for lung volume measurement. Based on Boyle's law (the inverse relationship between pressure and volume at constant temperature), plethysmography measures thoracic gas volume, including gas trapped behind closed airways and in non-communicating bullae. Helium dilution, a closed-circuit method, measures only the volume of gas that communicates with the airways during the test, and therefore underestimates true lung volumes in patients with severe obstruction or bullous disease, where trapped gas is excluded from equilibration. Nitrogen washout, an open-circuit technique, operates on a similar principle to helium dilution but may slightly overestimate volumes due to tissue nitrogen release. In practice, plethysmographic volumes typically exceed dilutional volumes by less than 500 mL in normal individuals. A discrepancy larger than this strongly suggests the presence of gas trapping or non-communicating bullous disease, and the magnitude of the discrepancy can provide clinically useful information about the severity of these processes.

### Key Volume and Capacity Definitions

Total lung capacity (TLC) represents the sum of all compartments of lung volume at maximal inflation. A TLC below the lower limit of normal defines restriction and is the only reliable method for confirming a restrictive ventilatory defect. Residual volume (RV) is the volume of gas remaining in the lungs after maximal expiration; its elevation is a hallmark of air trapping and hyperinflation. Functional residual capacity (FRC), the sum of expiratory reserve volume and residual volume, represents the resting end-expiratory lung volume and is determined by the balance between the outward elastic recoil of the chest wall and the inward elastic recoil of the lungs. Inspiratory capacity (IC), the sum of tidal volume and inspiratory reserve volume, is clinically important because a reduced IC/TLC ratio (less than 0.25) has been associated with increased mortality in COPD, as demonstrated by Casanova and colleagues. The RV/TLC ratio, when elevated above 0.40, provides a quantitative measure of air trapping and is highly relevant in the phenotyping of COPD patients and in guiding therapeutic decisions such as lung volume reduction.

### Patterns of Lung Volume Abnormalities

A restrictive pattern is defined by a TLC below the LLN. It is essential to recognize that a reduction in FVC on spirometry alone is insufficient to diagnose restriction, as this finding may result from air trapping with consequent elevation of RV, rather than from a true reduction in total lung volume. Hyperinflation is characterized by an elevated TLC above the upper limit of normal and is commonly observed in emphysema and severe asthma. Air trapping manifests as an elevated RV and/or RV/TLC ratio, with a normal or elevated TLC. A mixed obstructive-restrictive defect requires the presence of both obstruction on spirometry (reduced FEV1/FVC) and a reduced TLC, but the clinician must exercise caution, as FVC reduction from air trapping in the setting of obstruction can mimic restriction. Confirmation requires full lung volume measurement and careful clinical integration.

<image>A comprehensive chart showing four panels of lung volume compartments represented as stacked bar diagrams for: (1) normal, (2) obstructive disease with hyperinflation, (3) restrictive disease, and (4) mixed obstructive-restrictive pattern. Each bar should show TV, IRV, ERV, and RV as distinct colored segments with numerical values. Label TLC, VC, IC, FRC, and RV/TLC ratio for each pattern. Use a clean medical textbook style with a white background.</image>

## Flow-Volume Loop Pattern Recognition

### Upper Airway Obstruction

| Pattern | Lesion Location | Inspiratory Limb | Expiratory Limb | FEF50/FIF50 | Classic Examples |
|---------|----------------|-------------------|------------------|-------------|-----------------|
| Fixed obstruction | Any (tracheal) | Flattened | Flattened | ~1.0 | Tracheal stenosis, circumferential goiter |
| Variable extrathoracic | Above thoracic inlet | Flattened | Preserved | > 1.0 | Unilateral vocal cord paralysis, laryngeal mass |
| Variable intrathoracic | Below thoracic inlet | Preserved | Flattened | < 1.0 | Tracheomalacia, intrathoracic tracheal tumor |

The flow-volume loop provides critical information for the recognition of upper airway obstruction, which can be categorized by its location and dynamic behavior. Fixed upper airway obstruction, as seen in tracheal stenosis or a goiter compressing the trachea circumferentially, produces symmetrical flattening of both the inspiratory and expiratory limbs of the flow-volume loop, with the FEF50/FIF50 ratio approaching 1.0, reflecting the equal limitation of flow in both respiratory phases. Variable extrathoracic obstruction, exemplified by unilateral vocal cord paralysis, produces selective flattening of the inspiratory limb while preserving the expiratory limb. During inspiration, the negative intraluminal pressure generated to draw air into the lungs causes the extrathoracic airway to narrow at the site of the compliant obstruction, whereas during expiration, positive intraluminal pressure splints the airway open. This pattern yields an FEF50/FIF50 ratio greater than 1.0. Variable intrathoracic obstruction, as occurs in tracheomalacia or an intrathoracic tracheal tumor, produces the opposite pattern: flattening of the expiratory limb with preservation of the inspiratory limb. During expiration, positive intrathoracic pressure compresses the airway at the site of the lesion, while during inspiration, negative intrathoracic pressure opens the airway. The resulting FEF50/FIF50 ratio is less than 1.0.

### Suboptimal Effort and Artifacts

Recognition of suboptimal effort and artifact on the flow-volume loop is essential for quality assurance. Cough artifact appears as sudden spikes in flow during the expiratory phase, producing a jagged tracing. Glottic closure results in the abrupt termination of expiration at a volume well above the expected residual volume. Poor effort is characterized by variable peak flows across maneuvers and failure of the volume-time curve to reach a plateau. Hesitation at the start of the maneuver produces an excessively large back-extrapolated volume, indicating that the patient did not begin the forced expiratory effort promptly from full inspiration.

## Quality Assurance and Calibration

### Equipment Standards

Ensuring accuracy and reproducibility of spirometric measurements requires rigorous equipment calibration and maintenance. Volume-type spirometers must be verified daily using a calibrated 3-liter syringe to confirm that the measured volume falls within acceptable tolerances. Flow-type spirometers require linearity checks across a range of flows to ensure accurate measurement from low to high flow rates. All measured volumes must undergo BTPS correction, converting from ambient temperature and pressure to body temperature (37 degrees Celsius), ambient barometric pressure, and saturated water vapor conditions, as this standardization accounts for the expansion of gas as it warms and humidifies within the respiratory tract. Biological controls, in which laboratory staff perform spirometry on themselves at regular intervals, serve as an additional quality assurance measure to detect equipment drift over time.

### GLI Reference Equations

The Global Lung Initiative (GLI) 2012 reference equations represent a significant advance in PFT interpretation. Derived from a dataset of over 97,000 healthy individuals across 72 centers worldwide, these equations employ spline functions to model the complex, nonlinear relationships between lung function and age, height, and sex. The lower limit of normal is defined as the 5th percentile of the healthy reference population, corresponding to a z-score of -1.645. The use of z-scores is preferred over percent predicted for standardized interpretation, as z-scores provide a uniform metric for quantifying the degree of deviation from the predicted value, regardless of the parameter being measured or the age of the patient. The ATS 2023 statement has recommended the adoption of race-neutral reference equations, eliminating the prior practice of applying race- or ethnicity-specific adjustments. While this represents an important step toward addressing health equity, the clinical implications of this transition, particularly regarding the potential for misclassification of disease in certain populations, remain an active area of assessment and debate.

<image>A clinical algorithm flowchart for systematic PFT interpretation. Start with FEV1/FVC ratio assessment (normal vs. reduced). If reduced, classify as obstruction and grade severity by FEV1. If normal, check TLC: if low, restrictive; if normal, normal spirometry or early disease. Include bronchodilator response branch. Show decision nodes as diamonds, outcomes as rounded rectangles. Use color coding: blue for normal, red for obstruction, orange for restriction, purple for mixed. Include notation for when DLCO should be ordered.</image>

## Special Considerations

### Spirometry in Specific Populations

The interpretation of spirometry requires adaptation across specific clinical populations. In the elderly, shorter expiratory times may be accepted if a plateau has been achieved on the volume-time curve, and the use of the fixed FEV1/FVC ratio of 0.70 is particularly prone to overdiagnosing obstruction in this age group, making the LLN approach essential. In the pediatric population, GLI equations extend down to age 3, and coaching techniques must be adapted to the child's developmental stage, often requiring visual aids and games to elicit maximal effort. During pregnancy, FEV1 and FVC are generally preserved, while ERV and FRC decrease due to the upward displacement of the diaphragm by the gravid uterus; TLC is minimally affected, as the reduction in FRC is partly offset by an increase in inspiratory capacity. In obesity, ERV is markedly reduced and FRC is decreased, reflecting the mass-loading effect of adipose tissue on the chest wall and diaphragm; however, TLC is usually preserved unless the obesity is morbid (BMI above 40). In neuromuscular disease, FVC may be the only spirometric abnormality detected, and it is essential to measure FVC in both the upright and supine positions. A decline of more than 20% from upright to supine strongly suggests diaphragmatic weakness, as the supine position eliminates the gravitational assistance to diaphragmatic descent.

### Longitudinal Monitoring

Serial spirometric measurements provide valuable information about disease trajectory and treatment response. Normal FEV1 decline after age 35 is approximately 25 to 30 mL per year. An accelerated decline exceeding 40 to 60 mL per year suggests progressive disease, ongoing injurious exposure, or both, and should trigger a thorough clinical reassessment. When interpreting longitudinal data, the clinician must account for the expected degree of within-session variability (the coefficient of variation is approximately 5%) and the additional between-session variability that arises from differences in patient effort, equipment, and physiologic state between testing occasions.

## Key Clinical Pearls

- Never diagnose restriction on spirometry alone; a reduced FVC with obstruction more commonly reflects air trapping than coexistent restriction - confirm with TLC measurement
- The FEV1/FVC ratio should be compared to the LLN, not the fixed 0.70 cutoff, particularly in patients over 60 or under 40
- A significant difference between plethysmographic and dilutional lung volumes strongly suggests gas trapping or bullous disease
- Always interpret PFTs in context: a "normal" FEV1 in a previously athletic patient with a baseline FEV1 of 120% predicted may represent significant decline
- FEF25-75 in isolation should not drive clinical decisions; it has unacceptably high variability

<image>A side-by-side comparison of three flow-volume loops demonstrating upper airway obstruction patterns: (1) fixed upper airway obstruction with symmetrically flattened inspiratory and expiratory limbs, (2) variable extrathoracic obstruction with flattened inspiratory limb only, and (3) variable intrathoracic obstruction with flattened expiratory limb only. Include anatomical inset diagrams for each showing the location of the lesion and arrows indicating dynamic airway compression during inspiration and expiration. Label FEF50 and FIF50 on each loop.</image>

## References
1. Graham BL, Steenbruggen I, Miller MR, et al. Standardization of Spirometry 2019 Update: An Official American Thoracic Society and European Respiratory Society Technical Statement. Am J Respir Crit Care Med. 2019;200(8):e70-e88.
2. Quanjer PH, Stanojevic S, Cole TJ, et al. Multi-ethnic reference values for spirometry for the 3-95-yr age range: the global lung function 2012 equations. Eur Respir J. 2012;40(6):1324-1343.
3. Pellegrino R, Viegi G, Brusasco V, et al. Interpretative strategies for lung function tests. Eur Respir J. 2005;26(5):948-968.
4. Bhatt SP, Balte PP, Engel SM, et al. Race-Neutral Reference Equations for Spirometry: Rationale and Recommendations. Am J Respir Crit Care Med. 2023;207(12):1514-1521.
5. Wanger J, Clausen JL, Coates A, et al. Standardisation of the measurement of lung volumes. Eur Respir J. 2005;26(3):511-522.